Inhaled corticosteroids v placebo for chronic obstructive pulmonary disease at 24–40 months*
| Trials | Annual reduction in FEV1 decline (95% CI) |
|---|---|
| *Values are means. CI defined in glossary. A random effects model was used. | |
| All trials (8 trials, n = 3715) | 7.7 ml/y (1.3 to 14.2) |
| Trials with high-dose regimens (4 trials, n = 2416) | 9.9 ml/y (2.3 to 17.5) |